In Week of Mar 28, 2026, Corona Remedies Ltd (Pharma - Formulators) is outperforming Nifty 500 with +27.5% relative strength. Fundamentals: Weak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Mar 21, 2026
What: Launch of dedicated export business targeting Eurasian markets with multi-billion dollar potential
Impact: +₹500 Cr revenue
“Until now they've been a domestic powerhouse. Something like 96% of their revenue comes from India. So this is them starting a serious dedicated export engine.”
What: Revenue growing faster than costs creating strong operating leverage
“Revenue is up around 16% but profit is up almost 31%. That's some serious leverage.”
What: Strategic shift toward higher-margin chronic therapies through brand acquisitions
“They're focused on chronic therapies. They're buying up big brands from the giants.”
Earnings deceleration risks from management commentary
Trigger: Implementation of new labor codes
Impact: -50 bps margin impact
Management view: Profit after tax adjusted for the one-time impact of new labor codes stood at rupees 56 crores compared to 45 crores in Q3 FI25 reflecting a growth of around 24% YoY.
Monitor: PAT margin
Key quotes from recent conference calls
“The performance is aligned with our annual guidance of 15% revenue growth and 20% PAT growth. — Management”
“EBITDA margin improved by around 100 basis points and stood at 24.3%. — Management”
“Annualized ROCE for 9 months FY26 stood at 48%. — Management”
“We have transformed our aspiration of growing revenues by 15% and PAT by 20% into successful achievement. — Nurav Mtha, Managing Director”
Forward-looking targets from management for Next 2-4 quarters
Revenue Growth Target
15%
Implied PAT Growth
20%
Key Milestones
• 15% revenue growth
• 20% PAT growth
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +15% | +16% | Insufficient Data |
| PAT (Net Profit) | -9% | +32% | Insufficient Data |
| OPM | 24.0% | +100 bps | Expanding |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Mar 21, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Corona Remedies Ltd's latest quarterly results (Dec 2025) show
Corona Remedies Ltd's profit is declining with an insufficient_data trend.
Corona Remedies Ltd's revenue growth trend is insufficient_data.
Corona Remedies Ltd's operating margin is expanding.
Corona Remedies Ltd's long-term compounding rates
Corona Remedies Ltd's earnings growth is insufficient_data with mixed signals on a sequential basis.
Corona Remedies Ltd appears overvalued based on our fair value analysis.
Corona Remedies Ltd's current PE ratio is 60.6x.
Corona Remedies Ltd's current PE is 60.6x.
Corona Remedies Ltd's price-to-book ratio is 14.6x.
Corona Remedies Ltd is rated Weak with a fundamental score of 29.78/100. This score is calculated from objective financial metrics
Corona Remedies Ltd has a debt-to-equity ratio of N/A.
Corona Remedies Ltd's return ratios over recent years
Corona Remedies Ltd's operating cash flow is positive (FY2025).
Corona Remedies Ltd currently does not pay a significant dividend (yield 0.00%).
Corona Remedies Ltd's shareholding pattern (Dec 2025)
Corona Remedies Ltd has been outperforming Nifty 500 for 2 consecutive weeks, indicating early-stage outperformance.
Corona Remedies Ltd is an established outperformer with 2 weeks of consecutive Nifty 500 outperformance.
Corona Remedies Ltd has 3 key growth catalysts identified from recent earnings analysis
Corona Remedies Ltd has 1 key risk worth monitoring
In Q3 FY26, Corona Remedies Ltd's management highlighted
Corona Remedies Ltd's management has provided the following forward guidance for Next 2-4 quarters
Based on quantitative research signals, here is why Corona Remedies Ltd may be worth studying
Corona Remedies Ltd investment thesis summary:
Corona Remedies Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
